Interferon-beta 1b ( DrugBank: Interferon-beta )

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
13	多発性硬化症／視神経脊髄炎	5

13. 多発性硬化症／視神経脊髄炎

臨床試験数 : 3,342 / 薬物数 : 2,355 - (DrugBank : 406) / 標的遺伝子数 : 269 - 標的パスウェイ数 : 241

diseases per page:

Showing 1 to 5 of 5 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2012-005450-30-AT (EUCTR)	08/01/2014	11/11/2013	Investigation of neutralising antibodies against interferon-beta in patients with multiple sclerosis ...	Anti-Biopharmaceutical Immunization: Prediction and analysis of clinical relevance to minimize the r ...	Development of neutralising antibodies against Interferon-beta in the treatment of multiple sclerosi ...	Trade Name: Avonex INN or Proposed INN: Interferon-beta 1a Other descriptive name: INTERFERON BETA-1A T ...	Medizinische Universität Innsbruck	NULL	Not Recruiting			Female: yes Male: yes	100	Phase 4	Austria;Sweden
2	NCT00490906 (ClinicalTrials.gov)	June 2007	21/6/2007	Comparison of Bone Effects With Copaxone and Interferon in Multiple Sclerosis	Comparison of Bone Effects With Copaxone and Interferon in Multiple Sclerosis: A Pilot Study	Multiple Sclerosis;Low Bone Density	Drug: Copaxone;Drug: Interferon-beta 1a;Drug: Interferon-beta 1b	Nancy Hammond, MD	Kansas City Area Life Sciences Institute, Inc.	Completed	18 Years	N/A	Female	60	N/A	United States
3	NCT00468182 (ClinicalTrials.gov)	April 2007	30/4/2007	Modulation of Plasmacytoid Dendritic Cell Function in Multiple Sclerosis	Modulation of Plasmacytoid Dendritic Cell Function in Multiple Sclerosis	Multiple Sclerosis	Drug: Interferon-beta 1b (Betaseron)	Rutgers, The State University of New Jersey	Bayer	Completed	18 Years	60 Years	Both	24		United States
4	NCT01111656 (ClinicalTrials.gov)	March 2007	15/3/2010	Efficacy, Safety and Tolerability of Atorvastatin 40 mg in Patients With Relapsing-remitting Multipl ...	SWiss Atorvastatin and Interferon-Beta 1bTrial In Multiple Sclerosis - Follow up Study (SWABIMS Foll ...	Relapsing-remitting Multiple Sclerosis	Drug: Interferon beta-1b group;Drug: Interferon beta-1b/Atorvastatin group	University Hospital Inselspital, Berne	Viollier AG, Basel, Switzerland;PharmaPart GmbH, Thalwil, Switzerland	Completed	18 Years	67 Years	Both	28	Phase 2	Switzerland
5	NCT00942591 (ClinicalTrials.gov)	May 2005	17/7/2009	Atorvastatin 40 mg in Patients With Relapsing-Remitting Multiple Sclerosis Treated With Interferon-B ...	Efficacy, Safety and Tolerability of Atorvastatin 40 mg in Patients With Relapsing-remitting Multipl ...	Multiple Sclerosis	Drug: Interferon beta 1b;Drug: Atorvastatin	University Hospital Inselspital, Berne	CRO: PharmaPart AG, Bahnhofstrasse 20, P.O. Box 173, CH-8800 Thalwil;Laboratory: Viollier AG Spalenr ...	Completed	18 Years	55 Years	Both	77	Phase 2	Switzerland

First Previous1Next Last